Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robyn Hseu"'
Autor:
Liam F. Spurr, Carlos A. Martinez, Wenjun Kang, Mengjie Chen, Yuanyuan Zha, Robyn Hseu, Stanley I. Gutiontov, William T. Turchan, Connor M. Lynch, Kelli B. Pointer, Paul Chang, Septimiu Murgu, Aliya N. Husain, Brittany Cody, Everett E. Vokes, Christine M. Bestvina, Jyoti D. Patel, Maximilian Diehn, Thomas F. Gajewski, Ralph R. Weichselbaum, Steven J. Chmura, Sean P. Pitroda
Publikováno v:
Nature Cancer. 3:1498-1512
Over 500 clinical trials are investigating combination radiotherapy and immune checkpoint blockade (ICB) as cancer treatments; however, the majority of trials have found no positive interaction. Here we perform a comprehensive molecular analysis of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aea81f62ca731e975d213be7de47fdaa
https://doi.org/10.1038/s43018-022-00467-x
https://doi.org/10.1038/s43018-022-00467-x
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Purpose:CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6536beb4678e9cb73dd39e2e5832f0
https://doi.org/10.1158/1078-0432.c.6530619
https://doi.org/10.1158/1078-0432.c.6530619
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89653394de468c7c4c7a3b5bd38dc711
https://doi.org/10.1158/1078-0432.22481121
https://doi.org/10.1158/1078-0432.22481121